Latest Melanotan II Stories
CRANBURY, N.J., June 28, 2011 /PRNewswire/ -- Palatin Technologies, Inc.
CRANBURY, N.J., June 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal.
CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction.
CRANBURY, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc.
The U.S. Food and Drug Administration warned consumers about using Melanotan II , which is sold as a skin cancer preventative and tanning agent. The FDA announced Wednesday it had issued a warning letter to the product's manufacturer, Melanocorp Inc.
- Of or relating to good digestion.